false 0001427925 0001427925 2022-09-23 2022-09-23
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): September 23, 2022
 
ACELRX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
 
001-35068
 
41-2193603
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
25821 Industrial Boulevard, Suite 400
Hayward, CA
 
94545
(Address of Principal Executive Offices)
 
(Zip Code)
 

 
Registrant’s telephone number, including area code: (650) 216-3500
 
(Former name or Former Address, if Changed Since Last Report.)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on
which registered
Common Stock, $0.001 par value
 
ACRX
 
The Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 
Item 5.07
Submission of Matters to a Vote of Security Holders.
 
On September 23, 2022, AcelRx Pharmaceuticals, Inc. (the “Company”), convened a virtual special meeting of stockholders (the “Special Meeting”), to adopt and approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation and authorize the Board of Directors of the Company (the “Board”), in its sole discretion, to effect a reverse stock split of the outstanding shares of common stock of the Company (the “Common Stock”) at any time on or before the one year anniversary of the Special Meeting, at a reverse stock split ratio ranging from 1-for-10 to 1-for-30, as determined by the Board at a later date (the “Reverse Stock Split Proposal”).
 
At the Special Meeting, the stockholders voted on the Reverse Stock Split Proposal, which is described as Proposal 1 in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 12, 2022 (the “Proxy Statement”). Each of the 147,331,963 shares of Common Stock outstanding on the record date for the Special Meeting and present either by attendance via live webcast or by proxy was entitled to one vote per share on the Reverse Stock Split Proposal, and each of the 3,000 shares of Series A Preferred Stock of the Company (“Series A Preferred”), constituting 100% of the outstanding shares of Series A Preferred, outstanding on the record date for the Meeting, all of which were present by proxy at the Meeting, were entitled to 1,000,000 votes per share with respect to the Reverse Stock Split Proposal. As described in the Proxy Statement, shares of Series A Preferred may only vote on the Reverse Stock Split Proposal (and any related proposal to adjourn the meeting to solicit additional proxies with respect to such proposal), vote with the Common Stock as a single class, and are, to the extent cast, voted in the same proportion as the aggregate shares of Common Stock (excluding any shares of Common Stock that are not voted) are voted on the Reverse Stock Split Proposal.
 
The final results for the proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock were as follows:
 
With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 53,371,108; votes “Against” were 25,270,193; votes abstaining or withheld were 383,282, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows:
 
 
Votes For
Votes Against
Votes Abstaining
Broker Non-Votes
2,089,366,469
989,274,832
383,282
--
 
The proposal was approved.
 
1
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ACELRX PHARMACEUTICALS, INC.
Dated: September 23, 2022
By:
/s/ Raffi Asadorian
 
Name:
Raffi Asadorian
 
Title:
Chief Financial Officer
 
2
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AcelRX Pharmaceuticals Charts.
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AcelRX Pharmaceuticals Charts.